In Practice
Bookmark
Key facts
- Community pharmacies in England will be able to provide clinically appropriate prescription medicines via PGDs for seven common conditions in 2024
- The POM to P switch of tadalafil is a new treatment option for erectile dysfunction
- Semaglutide (Wegovy) is now licensed for obesity
- Emollient bath additives are no longer recommended in eczema (NICE update)
- Updates in NICE UTI guidelines pave the way for pharmacist consultations as part of the Pharmacy First common conditions programme (see also first bullet point)
- Pholcodine-containing medicines were withdrawn from the market in 2023.
Contributing author
Nicola Tyers, director, The Pharmacy Training Company and senior lecturer at Medway School of Pharmacy